For the past 40 years orthomolecular medicine has lead the way in establishing intravenous vitamin C (ascorbate) therapy as an adjunctive treatment in oncology and critical care. The Journal of Orthomolecular Medicine has published original research, synthesis papers, review articles, and case reports elucidating the pharmacokinetics, rationale, and evidence in support of intravenous vitamin C.
This important work has been developed and corroborated by an international consortium of clinicians and researchers who understand the therapeutic potential of this safe and cost-effective treatment. The Riordan Clinic, located in Wichita, KS, has been at the center of this work for the past 30 years, providing IVC treatment to tens of thousands of patients, training for hundreds of physicians and health care professionals, and conducting research for the advancement of intravenous vitamin C therapy.
The International Society for Orthomolecular Medicine is working to further disseminate information about the use of intravenous vitamin C, and will facilitate the presentation of an IV Vitamin C Academy, at the 46th Orthomolecular Medicine Today Conference in Toronto. The Academy will be presented by Ron Hunninghake, MD, Chief Medical Officer at the Riordan Clinic, and Tom Levy, MD, JD, author of Curing the Incurable, and Primal Panacea.
Upon completion of the IVC Academy, participants will be able to:
1. Evaluate the expanding scientific evidence for the pharmacokinetics of ascorbate;
2. Understand the current evidence for or against the use of intravenous vitamin C as an adjunctive chemotherapeutic agent and an intervention for sepsis in critical care settings;
3. Review the literature in support of ascorbate as an antimicrobial, antiviral and antitoxin;
4. Define the rationale for, and safe methods of administering IVC in a clinical setting;
5. Consider medical ethics and legal obligations when providing intravenous vitamin C therapy.